Navigation Links
Mylan Schedules Financial Results Conference Call and Live Webcast for the Second Quarter Fiscal 2008
Date:7/24/2008

PITTSBURGH, July 24 /PRNewswire-FirstCall/ -- Mylan Inc. (NYSE: MYL) announced today that it will host a conference call and live webcast on Wednesday, August 6, 2008, at 10:30 a.m. ET to provide a review of the second quarter ended June 30, 2008. The company will release its financial results before the market opens August 6.

The dial-in number to access the August 6 call is 877-741-4241 or 719-325-4787 for international callers. A replay, available for approximately seven days, will be available at 888-203-1112 or 719-457-0820 for international callers with access pass code 8142044.

To access a live webcast of the August 6 call, please log on to Mylan's Web site (http://www.mylan.com) at least 15 minutes before the event is to begin to register and download or install any necessary software. A replay of the webcast will be available on http://www.mylan.com for approximately seven days.

Mylan Inc., with operations in more than 90 countries, ranks among the leading diversified generic and specialty pharmaceutical companies in the world. The company maintains one of the industry's broadest -- and highest quality -- product portfolios, supported by a robust product pipeline; owns a controlling interest in the world's second largest active pharmaceutical ingredient manufacturer; and operates a specialty business focused on respiratory and allergy therapies. For more information about Mylan, visit http://www.mylan.com.


'/>"/>
SOURCE Mylan Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1

Related medicine news :

1. Daniel E. Crookshank Joins Mylan as Vice President - Investor Relations
2. Mylan Announces Tentative FDA Approval for Generic Version of Antibiotic Zyvox(R) Tablets
3. Mylan Announces Final FDA Approval for Generic Version of Antidepressant Effexor(R)
4. Mylan Announces Tentative FDA Approval for Generic Version of Antihypertensive Avalide(R) Tablets
5. Mylan Wins Generic Prilosec(R) Patent Litigation
6. Mylan Inc., NATCO Pharma Ltd. To Collaborate on Worldwide Marketing and Distribution of Generic Copaxone(R)
7. Mylan Announces Final FDA Approval for Zaleplon Capsules
8. Mylan Inc. Acquires Central Eastern European Generics Businesses of Merck KGaA
9. Mylan Launches Paroxetine Hydrochloride Extended-Release Tablets
10. Mylan Schedules Financial Results Conference Call and Live Webcast for the First Quarter Fiscal 2008
11. Mylan Declares Quarterly Preferred Stock Dividend
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/25/2017)... ... September 25, 2017 , ... ... excited to announce the next generation for LASIK in Manhattan with Contoura Vision, ... most technologically advanced laser systems available in the United States to correct nearsightedness ...
(Date:9/25/2017)... ... September 25, 2017 , ... ... Community”: a gripping look at the religious stand in the sensitive matter ... love and compassion. “The Ministry of Reconciliation: A Compassionate and Realistic Approach to ...
(Date:9/25/2017)... ... ... The trend-spotters, tastemakers, and healthy lifestyle product experts at the New ... with the new NEXTY Gold Award at the Natural Products Expo East trade show ... is reserved for just those companies that hit high marks on the criteria of ...
(Date:9/25/2017)... ... September 25, 2017 , ... ... September 28, 2017 to deliver a powerful message of teamwork, unity and collaboration ... Feature film writer/director Robert Adetuyi (Beat the World, Stomp the Yard) and Grammy-nominated ...
(Date:9/24/2017)... Michigan (PRWEB) , ... September 23, 2017 , ... Throughout ... do no harm. , Every day, physicians, nurses and other providers work to ... treatments and innovative industry processes. , But U.S. Senators today are threatening to ...
Breaking Medicine News(10 mins):
(Date:9/19/2017)... ANN ARBOR, Mich. , Sept. 19, 2017 HistoSonics, Inc., a venture-backed medical ... the precise destruction of targeted tissues, announced three leadership team developments today:   ... Josh Stopek, PhD ... ... Veteran medical device executive ...
(Date:9/12/2017)... and NEW YORK , Sept. 12, 2017 ... performance ratings for global supply chains, has published the first annual edition ... CSR performance of more than 20,400 companies evaluated by EcoVadis, based on ... 2015 and 2016. ... EcoVadis Global CSR Risk & Performance Index ...
(Date:9/9/2017)... 9, 2017  Eli Lilly and Company (NYSE: ... endpoint data for lasmiditan, an investigational, oral, first-in-class molecule ... significant improvements compared to placebo in the Phase 3 ... the 18th Congress of the International Headache Society (IHC) ... data presented today demonstrate lasmiditan,s potential to reduce pain ...
Breaking Medicine Technology: